Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
Shattuck Labs (NASDAQ: STTK) has secured an oversubscribed private placement expected to raise up to $103 million in gross proceeds. The financing includes initial proceeds of $46 million and potential additional proceeds of $57 million from warrant exercises.
The private placement, led by OrbiMed, involves issuing 15.2M shares of common stock and pre-funded warrants for 37.4M shares at $0.8677 per share, with accompanying warrants for 52.6M shares at $1.0846 exercise price. The proceeds will fund the clinical development of SL-325, a first-in-class DR3 blocking antibody for inflammatory bowel disease treatment, through multiple Phase 2 trials.
The financing is contingent upon IND clearance for SL-325, with the combined proceeds expected to fund operations into 2029.
Shattuck Labs (NASDAQ: STTK) ha ottenuto un collocamento privato sovrasottoscritto che dovrebbe raccogliere fino a 103 milioni di dollari di proventi lordi. Il finanziamento comprende proventi iniziali di 46 milioni di dollari e potenziali proventi aggiuntivi di 57 milioni di dollari derivanti dall'esercizio di warrant.
Il collocamento privato, guidato da OrbiMed, prevede l'emissione di 15,2 milioni di azioni ordinarie e warrant pre-finanziati per 37,4 milioni di azioni a 0,8677 dollari per azione, con warrant aggiuntivi per 52,6 milioni di azioni a un prezzo di esercizio di 1,0846 dollari. I proventi finanzieranno lo sviluppo clinico di SL-325, un anticorpo di prima classe che blocca DR3 per il trattamento della malattia infiammatoria intestinale, attraverso molteplici studi di Fase 2.
Il finanziamento 猫 subordinato all'approvazione IND per SL-325, e i proventi complessivi dovrebbero sostenere le operazioni fino al 2029.
Shattuck Labs (NASDAQ: STTK) ha asegurado una colocaci贸n privada sobresuscrita que se espera recaude hasta 103 millones de d贸lares en ingresos brutos. La financiaci贸n incluye ingresos iniciales de 46 millones de d贸lares y posibles ingresos adicionales de 57 millones de d贸lares provenientes del ejercicio de warrants.
La colocaci贸n privada, liderada por OrbiMed, implica la emisi贸n de 15,2 millones de acciones comunes y warrants prefinanciados para 37,4 millones de acciones a 0,8677 d贸lares por acci贸n, con warrants adicionales para 52,6 millones de acciones a un precio de ejercicio de 1,0846 d贸lares. Los ingresos financiar谩n el desarrollo cl铆nico de SL-325, un anticuerpo bloqueador de DR3 de primera clase para el tratamiento de la enfermedad inflamatoria intestinal, a trav茅s de m煤ltiples ensayos de Fase 2.
La financiaci贸n est谩 condicionada a la aprobaci贸n IND para SL-325, y se espera que los ingresos combinados financien las operaciones hasta 2029.
Shattuck Labs (NASDAQ: STTK)電� 斓滊寑 1鞏� 300毵� 雼煬鞚� 齑� 靾橃澋鞚� 鞓Υ 瓴冹溂搿� 鞓堨儊霅橂姅 齑堦臣 觳暯霅� 靷 鞙犾儊歃濎瀽毳� 頇曤炒頄堨姷雼堧嫟. 鞚措矆 鞛愱笀 臁半嫭鞐愲姅 齑堦赴 靾橃澋 4,600毵� 雼煬鞕� 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 於旉皜 鞛犾灛 靾橃澋 5,700毵� 雼煬臧� 韽暔霅╇媹雼�.
OrbiMed臧� 欤茧弰頃橂姅 鞚措矆 靷 鞙犾儊歃濎瀽電� 氤错喌欤� 1,520毵� 欤检檧 欤茧嫻 0.8677雼煬鞐� 雽�頃� 3,740毵� 欤检潣 靹犾旮� 鞗岆煱韸鸽ゼ 氚滍枆頃橂┌, 頄夓偓 臧�瓴╈澊 1.0846雼煬鞚� 5,260毵� 欤检潣 鞗岆煱韸鸽弰 頃粯 氚滍枆霅╇媹雼�. 靾橃澋旮堨潃 鞐检靹� 鞛� 歆堩櫂 旃橂毳� 鞙勴暅 斓滌磮鞚� DR3 彀嫧 頃泊鞚� SL-325鞚� 鞛勳儊 臧滊皽, 雼れ垬鞚� 2靸� 鞁滍棙 歆勴枆鞐� 靷毄霅� 鞓堨爼鞛呺媹雼�.
鞚措矆 鞛愱笀 臁半嫭鞚� SL-325鞚� IND 鞀轨澑鞐� 雼牑 鞛堨溂氅�, 齑� 靾橃澋旮堨潃 2029云�旯岇 鞖挫榿 鞛愱笀鞚� 歆�鞗愴暊 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
Shattuck Labs (NASDAQ : STTK) a s茅curis茅 un placement priv茅 sursouscrit, qui devrait permettre de lever jusqu'脿 103 millions de dollars de produit brut. Le financement comprend des produits initiaux de 46 millions de dollars et des produits suppl茅mentaires potentiels de 57 millions de dollars provenant de l'exercice de bons de souscription.
Le placement priv茅, men茅 par OrbiMed, implique l'茅mission de 15,2 millions d'actions ordinaires et de bons de souscription pr茅financ茅s pour 37,4 millions d'actions 脿 0,8677 dollar par action, avec des bons de souscription accompagnants pour 52,6 millions d'actions 脿 un prix d'exercice de 1,0846 dollar. Les fonds serviront 脿 financer le d茅veloppement clinique de SL-325, un anticorps bloquant DR3 de premi猫re classe pour le traitement des maladies inflammatoires de l'intestin, 脿 travers plusieurs essais de phase 2.
Le financement est conditionn茅 脿 l'autorisation IND pour SL-325, les produits combin茅s devant permettre de financer les op茅rations jusqu'en 2029.
Shattuck Labs (NASDAQ: STTK) hat eine 眉berzeichnete Privatplatzierung gesichert, die voraussichtlich bis zu 103 Millionen US-Dollar Bruttoerl枚se einbringen wird. Die Finanzierung umfasst anf盲ngliche Erl枚se von 46 Millionen US-Dollar sowie potenzielle zus盲tzliche Erl枚se von 57 Millionen US-Dollar aus der Aus眉bung von Warrants.
Die von OrbiMed gef眉hrte Privatplatzierung beinhaltet die Ausgabe von 15,2 Millionen Stammaktien und vorfinanzierten Warrants f眉r 37,4 Millionen Aktien zu 0,8677 US-Dollar pro Aktie, mit begleitenden Warrants f眉r 52,6 Millionen Aktien zu einem Aus眉bungspreis von 1,0846 US-Dollar. Die Erl枚se werden die klinische Entwicklung von SL-325 finanzieren, einem neuartigen DR3-blockierenden Antik枚rper zur Behandlung entz眉ndlicher Darmerkrankungen, durch mehrere Phase-2-Studien.
Die Finanzierung ist abh盲ngig von der IND-Freigabe f眉r SL-325, wobei die kombinierten Erl枚se voraussichtlich den Betrieb bis 2029 finanzieren werden.
- Significant funding secured with $103M potential total gross proceeds
- Strong investor participation from both new and existing healthcare-focused funds
- Extended cash runway into 2029
- Development funding secured for multiple Phase 2 clinical trials
- Strategic timing with Phase 1 trial enrollment expected this quarter
- Significant dilution through issuance of 15.2M shares and potential 37.4M additional shares
- Financing contingent on IND clearance for SL-325
- Warrants create potential future dilution if exercised
- Shares and warrants issued at significant discount to market price
Insights
Shattuck's $103M financing provides critical runway through 2029, funding multiple Phase 2 trials for potentially first-in-class DR3 inhibitor.
This $103 million oversubscribed private placement represents a significant financial milestone for Shattuck Labs, particularly impressive in today's challenging biotech funding environment. The transaction structure is notably complex, with 15.2 million common shares and 37.4 million pre-funded warrants, plus accompanying warrants that could bring an additional $57 million upon exercise.
The financing was led by heavyweight investor OrbiMed, alongside both new and existing investors including Redmile and Adage Capital 鈥� a strong signal of institutional confidence in Shattuck's scientific approach targeting DR3 rather than TL1A. The extended cash runway into 2029 provides exceptional operational stability, essentially removing financing risk for the foreseeable future.
Most critically, this capital infusion enables Shattuck to advance SL-325 through multiple Phase 2 trials without requiring additional fundraising between clinical inflection points. The focus on IBD (Crohn's disease and ulcerative colitis) positions SL-325 in a substantial market with significant unmet needs despite recent TL1A inhibitor advancements.
The timing of this raise ahead of IND clearance and Phase 1 initiation is strategically optimal, as it allows Shattuck to negotiate from a position of strength with potential future partners after generating Phase 1 data. The warrant exercise trigger being tied specifically to Phase 1 data readout and Phase 2 design announcement creates a structured capital infusion timeline aligned with clinical development milestones.
鈥� Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease 鈥�
鈥� Pro forma cash and cash equivalents from aggregate proceeds anticipated to fund operations into 2029 鈥�
AUSTIN, TX and DURHAM, NC, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that it has entered into a securities purchase agreement for a private placement financing that is expected to result in total gross proceeds of up to approximately
The private placement听was led by OrbiMed and with participation from both new and existing investors, including: a large healthcare-dedicated fund, Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital.
The private placement will be for an aggregate of 15,225,158 shares of the Company鈥檚 common stock and, to certain investors, pre-funded warrants to purchase an aggregate of 37,410,188 shares of common stock, along with accompanying warrants to purchase an aggregate of 52,635,346 shares of common stock (or, in lieu thereof, additional pre-funded warrants). The purchase price for each share of common stock and accompanying warrant is
鈥淪L-325 is a potentially first-in-class DR3 blocking antibody intended for development in Crohn鈥檚 disease, ulcerative colitis, and a range of other autoimmune and inflammatory diseases,鈥� said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. 鈥淓nrollment in our Phase 1 clinical trial for SL-325 is expected to begin this quarter, subject to regulatory alignment, and this financing will allow us to transition seamlessly into multiple Phase 2 clinical trials, where the data will reveal whether DR3 blockade leads to both superior efficacy and reduced immunogenicity in comparison to TL1A blocking antibodies.鈥�
The Company anticipates the initial gross proceeds from the private placement to be approximately听
Shattuck intends to use the anticipated net proceeds from the private placement (including the potential proceeds to be received upon the full exercise of the accompanying common stock warrants) for the clinical development of SL-325, including multiple Phase 2 clinical trials, including in IBD and another autoimmune disease, SL-425, and for general corporate purposes. The total proceeds from the private placement (including full exercise of the accompanying common stock warrants), combined with current cash and cash equivalents, are expected to fund operations into 2029.
Wedbush & Co., LLC is acting as the sole placement agent in connection with the private placement.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in听the United States听except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.听Shattuck has agreed to file a registration statement with the听Securities and Exchange Commission (SEC)听registering the resale of the shares of common stock purchased in the private placement and shares听of common stock听underlying the warrants.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck鈥檚 preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. Shattuck expects to commence a Phase 1 clinical trial in healthy volunteers in the third quarter of 2025.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck鈥檚 expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a potential first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .听
Forward-Looking Statements
Certain statements in this press release may constitute 鈥渇orward-looking statements鈥� within the meaning of the federal securities laws, including, but not limited to, our expectations regarding: the aggregate amount of proceeds to be received from the private placement, including whether the common stock warrants will be exercised and provide the Company with additional capital; the closing of the private placement and associated satisfaction of closing conditions, including with respect to clearance of the Company鈥檚 IND; the use of proceeds from the private placement; the timing for enrollment of the Phase 1 trial for SL-325; anticipated Phase 2 clinical trials for SL-325; and the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渙bjective,鈥� 鈥渋ntend,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渃an,鈥� 鈥渨ould,鈥� 鈥渆xpect,鈥� 鈥渂elieve,鈥� 鈥渄esign,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥渄evelop,鈥� 鈥減lan鈥� or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the SEC), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility; expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals, including FDA clearance of our IND filing; our expectations regarding the overall benefit of the strategic prioritization of our pipeline; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent disclosure documents filed with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
听
FAQ
How much money did Shattuck Labs (STTK) raise in the August 2025 private placement?
What is the purpose of Shattuck Labs' (STTK) $103M private placement funding?
Who were the major investors in Shattuck Labs' August 2025 private placement?
What is the pricing structure of Shattuck Labs' private placement offering?
How long will the funding from STTK's private placement last?
What is SL-325 and what is its potential market impact?
